(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, a division of L ... In June 2009, he joined Sanofi Pasteur as Vice President, Franchise &amp, Global Marketing Operations ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...

Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...

(Bloomberg) -- After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into ...

Sanofi and Sudair Pharma Company (SPC) have joined forces to establish a state-of-the-art manufacturing facility within the Kingdom of Saudi Arabia, dedicated to the full production including delivery ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...

French pharmaceutical company Sanofi has entered exclusive talks to sell a 50% stake in its consumer health business Opella to U.S. private equity firm CD&R, with Bpifrance acquiring a 2% share. The ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...